Yunxin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yunxin Wang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
B. Liu
The Second Affiliated Hospital Shaanxi University of Chinese Medicine Xi'an China
1 shared publication- Chunxia Gao
College of Marine Living Resource Sciences and Management, Shanghai Ocean University, Shanghai, 201306, China; Key Laboratory of Sustainable Exploitation of Oceanic Fisheries Resources, Ministry of Education, Shanghai, 201306, China; Key Laboratory of Oceanic Fisheries Exploration, Ministry of Agriculture and Rural Affairs, Shanghai, 201306, China; National Engineering Research Centre for Oceanic Fisheries, Shanghai Ocean University, Shanghai, China
1 shared publication - Fan Shi
Department of Radiation Oncology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China
1 shared publication - Feng Zhang
Department of Radiotherapy, The Second Hospital of Dalian Medical University, Dalian, Liaoning Province, China
1 shared publication Fuxiu Ye
Department of Radiation Oncology The Second Affiliated Hospital of Dalian Medical University Dalian China
1 shared publication- Haichen Zhang
Department of Radiation Oncology The Second Affiliated Hospital of Dalian Medical University Dalian China
1 shared publication
Latest Publications
- Open Access
- 19 August 2024
- Published by Wiley in Cancer Reports
- Vol. 7 (8) , e2147
Efficacy and Safety of 125I Seed Implantation in the Treatment of Pelvic Recurrent Cervical Cancer Following Radiotherapy: A Single‐Arm Meta‐Analysis of Chinese Patients
Background: The study aimed to assess the efficacy and safety of 125I seed implantation in the treatment of pelvic recurrent cervical cancer following radiotherapy. This meta‐analysis was registered in PROSPERO. We looked up relevant studies in the databases of CNKI, Wanfang, CBM, PubMed, Embase, Cochrane Library, and Web of Science. The endpoint measures include the objective response rate, disease control rate, progression‐free survival, overall survival, and adverse events.Recent Fidings: The meta‐analysis included six studies and a total of 246 patients. The pooled ORR of tumor response was 63%, and the DCR was 87%. The median PFS was 9.09 months, and the median OS was 13.46 months. The incidence of adverse events of Grade ≥III was 6%.Conclusion: In conclusion, this meta‐analysis confirmed that 125I seed implantation has a good local control rate and high safety in the treatment of pelvic recurrent cervical cancer following radiotherapy, and can be used as a remedial treatment for pelvic recurrent cervical cancer following radiotherapy to prolong the survival time of patients.Trial Registration: PROSPERO: CRD42023423857
- 19 August 2024
- Published by Wiley in Cancer Reports
- Vol. 7 (8) , e2147
Open AccessEfficacy and Safety of 125I Seed Implantation in the Treatment of Pelvic Recurrent Cervical Cancer Following Radiotherapy: A Single‐Arm Meta‐Analysis of Chinese Patients
Background: The study aimed to assess the efficacy and safety of 125I seed implantation in the treatment of pelvic recurrent cervical cancer following radiotherapy. This meta‐analysis was registered in PROSPERO. We looked up relevant studies in the databases of CNKI, Wanfang, CBM, PubMed, Embase, Cochrane Library, and Web of Science. The endpoint measures include the objective response rate, disease control rate, progression‐free survival, overall survival, and adverse events.Recent Fidings: The meta‐analysis included six studies and a total of 246 patients. The pooled ORR of tumor response was 63%, and the DCR was 87%. The median PFS was 9.09 months, and the median OS was 13.46 months. The incidence of adverse events of Grade ≥III was 6%.Conclusion: In conclusion, this meta‐analysis confirmed that 125I seed implantation has a good local control rate and high safety in the treatment of pelvic recurrent cervical cancer following radiotherapy, and can be used as a remedial treatment for pelvic recurrent cervical cancer following radiotherapy to prolong the survival time of patients.Trial Registration: PROSPERO: CRD42023423857
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , e473
Radiation-induced Vaginal Injury After Treatment for Cervical Cancer
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , e473
Radiation-induced Vaginal Injury After Treatment for Cervical Cancer